Home › Soft Tissue Sarcoma › NCT04506008

Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas

Prospective Observational Trial of Two Neoadjuvant Hypofractionated Radiotherapy Regimens Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Histologic diagnosis of a soft tissue sarcoma of extremity, pelvis, chest wall or trunk/abdominal wall (non-retroperitoneal location)
* ECOG performance status 0-2
* Patient must be deemed able to comply with radiation treatment and surgery

Exclusion Criteria:

* History of prior radiation to the same area to be irradiated
* Pregnancy
* Active collagen vascular disease or patients genetically predisposed to increased radiation related side effects

About the study

The trial will use neoadjuvant hypofractionated radiotherapy followed by surgical resection in the treatment for soft tissue sarcoma. It will allow patients to be treated over a shorter course (5 or 15 days of radiation) compared to the traditional 5 week regimen. It is proposed that this will be possible without increasing the risk of wound complication or local recurrence compared with a traditional 5 week course of pre-operative radiation.

What is being tested

• Ultra-Hypo-fractionation Radiotherapy (radiation)
• Resection (procedure)
• Questionnaire Administration (other)
• Moderately-Hypo-fractionation Radiotherapy (radiation)

Sponsor: Vanderbilt-Ingram Cancer Center · Participants: 40 · Started: Mar 2, 2021

Contact the study team

• Vanderbilt-Ingram Service for Timely Access · Phone: 800-811-8480

Official record on ClinicalTrials.gov — NCT04506008

Locations in the U.S.

Conditions

• Soft Tissue Sarcoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.